ROCKVILLE, MD and SHENZHEN, CHINA, September 30, 2024—HighTide Therapeutics, Inc. (2511.HK), a clinical stage biopharmaceutical company specializing in the development of multifunctional multi-targeted therapies for chronic liver and metabolic diseases, announced today thatDr.Leigh MacConell, Chief Development Officer will present at the H.C. Wainwright 8th Annual MASH Investor Conference. Additionally, the Company’s Management will participate invirtualone-on-one investor meetings.

Speaker: Dr.Leigh MacConell

Format:Presentation

Date: Monday, October 7, 2024

Time: 3:00 PM ET

About HighTide Therapeutics

HighTide Therapeutics, Inc. (2511.HK) is a globally integrated biopharmaceutical company focusing on the discovery and development of first-in-class multifunctional multi-targeted therapies with chronic liver and metabolic diseases with significant unmet medical needs. The company is developing multiple clinical assets, including therapy for metabolic dysfunction-associated steatohepatitis (MASH), type 2 diabetes (T2DM), severe hypertriglyceridemia (SHTG), primary sclerosing cholangitis (PSC). Berberine ursodeoxycholate (HTD1801), the company’s lead drug candidate, received Fast Track designation from the U.S. FDA for bothMASH and PSC, as well as Orphan Drug designation for PSC. In China, HTD1801 has been included in the National Major New Drug Innovation Program under the 13th Five-Year Plan for Major Technology Project.

For more information, please visit www.hightidetx.com

Contact: pr@hightidetx.com